A randomized, double-blind, placebo- controlled, multicenter, Phase 3, PIVOTAL study with an open-label Extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with Myelin oligodendrocyte glycoprotein (MOG) ANTIBODY-ASSOCIATED disease (MOG-AD).

Project: Research

Project Details

StatusActive
Effective start/end date13/05/22 → 31/12/26

Keywords

  • Neurological diseases
  • Myelin oligodendrocyte glycoprotein
  • Clinical trial